Answers are grounded in this paper and cite their sources.
Bispecific ADCs (bsADCs) are positioned as an emerging, next-generation, class of therapeutics, combining the dual-targeting capabilities of bispecific antibodies (bsAbs) with the potent cytotoxicity of antibody-drug conjugates (ADCs). The resulting bsADC offers improved efficacy and safety for the treatment of heterogeneous solid tumors.
No takes yet. Share an insight, caveat, or question.
Peter Hofland (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: